Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
Teva's pivot from generics to branded drugs has succeeded, but keep an eye out for this potential headwind.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
